Etofibrate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{drugbox
{{Drugbox
| IUPAC_name       = 2-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}ethyl nicotinate
| Watchedfields = changed
| image             = Etofibrate svg.png
| verifiedrevid = 443303349
| CAS_number        = 31637-97-5
| IUPAC_name = 2-[(pyridin-3-yl)carbonyloxy]ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
| ATC_prefix        = C10
| image =Etofibrate.png
| ATC_suffix        = AB09
| width = 300
| PubChem          = 65777
| image2 =Etofibrate 3D spacefill.png
| DrugBank          =
| alt2 = Space-filling model of the etofibrate molecule
| C=18|H=18|Cl=1|N=1|O=5
 
| molecular_weight  = 363.792 g/mol
<!--Clinical data-->
| bioavailability  =
| tradename =
| protein_bound    =
| Drugs.com = {{drugs.com|international|etofibrate}}
| metabolism        = [[Hydrolysis|Hydrolyzed]] to clofibric acid and [[niacin]]
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| elimination_half-life =
| pregnancy_US = <!-- A / B            / C / D / X -->
| excretion        =
| pregnancy_category =   
| pregnancy_AU     = <!-- A / B1 / B2 / B3 / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| pregnancy_US     = <!-- A / B            / C / D / X -->
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| pregnancy_category=   
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_AU         = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_CA         = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_status =
| legal_UK         = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| routes_of_administration =
| legal_US         = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status     =  
| routes_of_administration =  
}}
{{SI}}
{{CMG}} 


<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = [[Hydrolysis|Hydrolyzed]] to clofibric acid and [[niacin]]
| elimination_half-life = 
| excretion = 


<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 31637-97-5
| ATC_prefix = C10
| ATC_suffix = AB09
| PubChem = 65777
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08983
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 59197
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 23TF67G79M
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07187
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 358150


<!--Chemical data-->
| C=18 | H=18 | Cl=1 | N=1 | O=5
| molecular_weight = 363.792 g/mol
| smiles = O=C(OCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)c2cccnc2
| InChI = 1/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3
| InChIKey = XXRVYAFBUDSLJX-UHFFFAOYAL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XXRVYAFBUDSLJX-UHFFFAOYSA-N
}}
__Notoc__
{{SI}}
{{CMG}}
==Overview==
==Overview==
'''Etofibrate''' is a [[fibrate]]. It is a combination of [[clofibrate]] and [[niacin]], linked together by an [[ester]] bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to [[Sustained release|controlled-release]] formulations.<ref>{{cite journal |author=Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA |title=Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects |journal=Braz J Med Biol Res |volume=34 |issue=2 |pages=177–82 |year=2001 |pmid=11175492 |doi=}} [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000200004 Free full text]</ref>
 
'''Etofibrate''' is a [[fibrate]]. It is a combination of [[clofibrate]] and [[niacin]], linked together by an [[ester]] bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to [[Sustained release|controlled-release]] formulations.<ref>{{cite journal |author=Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA |title=Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects |journal=Braz J Med Biol Res |volume=34 |issue=2 |pages=177–82 |year=2001 |pmid=11175492 |doi=10.1590/S0100-879X2001000200004}} [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000200004 Free full text]</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{Lipid modifying agents}}


[[Category:Fibrates]]
[[Category:Fibrates]]
[[Category:Prodrugs]]
[[Category:Organochlorides]]
[[Category:Organochlorides]]
[[Category:Phenol ethers]]
[[Category:Phenol ethers]]
[[Category:Nicotinates]]
[[Category:Nicotinates]]
[[Category:Prodrugs]]
[[Category:Drug]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 20:10, 14 April 2015

Etofibrate
Space-filling model of the etofibrate molecule
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Pharmacokinetic data
MetabolismHydrolyzed to clofibric acid and niacin
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H18ClNO5
Molar mass363.792 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Etofibrate

Articles

Most recent articles on Etofibrate

Most cited articles on Etofibrate

Review articles on Etofibrate

Articles on Etofibrate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Etofibrate

Images of Etofibrate

Photos of Etofibrate

Podcasts & MP3s on Etofibrate

Videos on Etofibrate

Evidence Based Medicine

Cochrane Collaboration on Etofibrate

Bandolier on Etofibrate

TRIP on Etofibrate

Clinical Trials

Ongoing Trials on Etofibrate at Clinical Trials.gov

Trial results on Etofibrate

Clinical Trials on Etofibrate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Etofibrate

NICE Guidance on Etofibrate

NHS PRODIGY Guidance

FDA on Etofibrate

CDC on Etofibrate

Books

Books on Etofibrate

News

Etofibrate in the news

Be alerted to news on Etofibrate

News trends on Etofibrate

Commentary

Blogs on Etofibrate

Definitions

Definitions of Etofibrate

Patient Resources / Community

Patient resources on Etofibrate

Discussion groups on Etofibrate

Patient Handouts on Etofibrate

Directions to Hospitals Treating Etofibrate

Risk calculators and risk factors for Etofibrate

Healthcare Provider Resources

Symptoms of Etofibrate

Causes & Risk Factors for Etofibrate

Diagnostic studies for Etofibrate

Treatment of Etofibrate

Continuing Medical Education (CME)

CME Programs on Etofibrate

International

Etofibrate en Espanol

Etofibrate en Francais

Business

Etofibrate in the Marketplace

Patents on Etofibrate

Experimental / Informatics

List of terms related to Etofibrate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.[1]

References

  1. ↑ Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res. 34 (2): 177–82. doi:10.1590/S0100-879X2001000200004. PMID 11175492. Free full text
Retrieved from "https://www.wikidoc.org/index.php?title=Etofibrate&oldid=1087446"